Related Experiment Video
Updated: May 9, 2026
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
The effect of the EXOPULSE Mollii suit on motor functions in patients with multiple sclerosis - a randomized
Samar S Ayache1, Joseph G Mattar1, Alain Créange2
1Institut de la Colonne Vertébrale et des Neurosciences (ICVNS), Centre Médico Chirurgical Bizet, Paris, France.
Background:
Patients with multiple sclerosis (PwMS) could suffer from frequent and disabling motor symptoms, including balance and mobility problems, spasticity, weakness and fatigue, with an impact on patients' quality of life. Current treatments have limited efficacy or significant side effects. The EXOPULSE Mollii Suit, a transcutaneous electrical nerve stimulation system, provides simultaneous stimulation to 40 muscle groups and may offer a therapeutic alternative.
Objectives:
This study evaluated the effects of this device on balance, other motor symptoms and quality of life in PwMS.
Methods:
A randomized, crossover, sham-controlled, double-blind study (phase 1) evaluated the effects of a 60-min single session of active versus sham stimulation. An open-label phase 2 evaluated the effects of stimulation over four weeks. Balance (Berg Balance Scale) was the primary outcome, with secondary measures including spasticity, mobility, pain, fatigue and quality of life.
Results:
Thirty-two patients completed phase 1, and 30 completed phase 2. The intervention was well tolerated. Significant improvements in balance (p < 0.001), spasticity (p < 0.001) and fatigue (p = 0.007) were observed in phase 1. Phase 2 showed sustained improvements in balance, spasticity, mobility and quality of life (p < 0.05).
Conclusions:
The EXOPULSE Molii Suit demonstrated significant benefits for motor symptoms, warranting further large-scale research into long-term effects.This clinical trial was prospectively registered on clinicaltrials.gov as 'EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP)' (NCT06702137). https://clinicaltrials.gov/study/NCT06702137?term=NCT06702137&rank=1.
